Wouldn't it make more sense to run a PH II trial to assess whether there's any merit to using Pima as the sole tx for that Subset of Schizophrenia it might address?
Adding it to an existing anti-psychotic seems likely to give ambiguous results rather than answering any meaningful questions.
i.e. Which tx contributed to the benefit, or mostly so? Did the anti-psychotic interfere with Pima? Does Pima treat the negative symptom subset of Shizo?
If its effective against this subset, there's about 1.5M pts in the US alone. If they could capture 10 to 20% of that population, the revenue would be quite significant for ACAD.
From anecdotal evidence, I strongly believe that MDD will alone make Pima a blockbuster tx. Getting AD Psychosis added to the label would be 'gravy'.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.